Business Today
Loading...

Atma Nirbhar Bharat: Here are 53 drugs on which India will test self-reliance

The government strategy is expected to reduce dependence on China and be self reliant on the production of live saving and critical medicines throughout its production chain

twitter-logoJoe C Mathew | June 3, 2020 | Updated 11:38 IST
Atma Nirbhar Bharat: Here are 53 drugs on which India will test self-reliance

The government has notified the production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (drug intermediates) and active pharmaceutical ingredients (bulk drugs) in India. The scheme, open for four months from June 2, will allow investors to propose establishment of greenfield facilities for any of the 53 key drug intermediates and bulk drugs that are hardly manufactured in India today. The list includes key ingredients that go into the manufacturing of commonly prescribed medicines like paracetamol, aspirin, metformin, atorvastatin etc.

Bulk of the imports of these drug intermediates and bulk drugs are from China. The government strategy is expected to reduce dependence on China and be self reliant on the production of live saving and critical medicines throughout its production chain.

For fermentation-based eligible products, the scheme provides 20 percent of the annual incremental sales of these products for the first four years. For the fifth and sixth year, the incentive will be 15 percent and 5 percent respectively. For products that are chemically synthesised, it will be 10 percent incentive on the incremental sales for the first five years. The government proposes to spend a total of Rs 6,940 crore as incentive during the tenure of the scheme.  

The notification on June 2 by the department of pharmaceuticals also specifies that the eligibility for the incentive scheme will depend on companies' threshold investment to set up the greenfield manufacturing unit. Functional guidelines for the operationalisation of the scheme is to be issued by the department soon.

The complete list of products identified are as follows:

1. Amoxicillin

2. Azithromycin

3. Erythromycin Stearate/Estolate

4. Ceftriaxone

5. Cefoperazone

6. Cefixime

7. Cephalexin

8. Piperacillin Tazobactam

9. Sulbactam

10. Dexamethasone

11. Prednisolone

12. Metformin

13. Gabapentin

14. Rifampicin

15. Vitamin B1

16. Vitamin B6

17. Clindamycin Phosphate

18. Clindamycin HCL

19. Streptomycin

20. Neomycin

21. Gentamycin

22. Doxycycline

23. Potassium Clavulanate

24. Oxytetracycline

25. Tetracycline

26. Clarithromycin

27. Betamethasone

28. Ciprofloxacin

29. Losartan

30. Telmisartan

31. Artesunate

32. Norfloxacin

33. Ofloxacin

34. Metronidazole

35. Sulfadiazine

36. Levofloxacin

37. Meropenem

38. Paracetamol

39. Tinidazole

40. Ornidazole

41. Ritonavir

42. Doclofinac Sodium

43. Aspirin

44. Levetiracetam

45. Carbidopa

46. Levodopa

47. Carbamazepine

48. Oxcarbazepine

49. Valsartan

50. Olmesartan

51. Atorvastatin

52. Acyclovir

53. Lopinavir

Also read: Make in India: DPIIT revises guidelines for procurement of chemicals, petrochemicals

Youtube
  • Print

  • COMMENT
BT-Story-Page-B.gif
A    A   A
close